Page 3 - Eric Soyer News Today

Review of the true value of Erytech's assetsProposed strategy for ErytechAudit report requested by Akkadian stating the undervaluation of Erytechand the overvaluation of Phereceydes in the 1:1 parity adopted

Akkadian Suggests to Erytech an Alternative Strategy to its Merger ...

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023 Cambridge, MA and Lyon , May 24, 2023 – ERYTECH Pharma , a clinical-stage... | June 11, 2023

ERYTECH Announces the Availability of the Documents for its Annual General Meeting to be held on June 23, 2023 Cambridge, MA (U.S.) and Lyon (France), May 24, 2023 - ERYTECH Pharma (Nasdaq &

PRESS RELEASE ERYTECH announces the availability of the exemption document relating to the proposed combination with Pherecydes Lyon , May 23, 2023 - ERYTECH Pharma , a clinical-stage... | May 23, 2023

▪Entry into a definitive merger agreement between ERYTECH and PHERECYDES ▪Completion of a contribution in kind of PHERECYDES shares to ERYTECH ... | May 16, 2023

ERYTECH Provides Update on the Announced Combination with PHERECYDES         Entry into a definitive merger agreement between ERYTECH and PHERECYDESCompletion... | May 15, 2023

ERYTECH Provides Update on the Announced Combination with PHERECYDES Entry into a definitive merger agreement between ERYTECH and PHERECYDESCompletion of a contribution in kind of PHERECYDES

ERYTECH Provides Business and Financial Update for the First Quarter of 2023 Combination with Pherecydes, intending to create a global leader in extended phage therapies to target antimicrobial

ERYTECH Announces Approval to Transfer its Listing to the Nasdaq Capital Market Cambridge, MA (U.S.) and Lyon (France), April 17, 2023 - ERYTECH Pharma (Nasdaq & Euronext: a clinical-stage